FeesSafety
Pluang+

WhiteFiber reports Q3 revenue growth, $300M financing, and $700M new cloud contracts boosting 2027 outlook

Company Fundamentals
10 Nov 2026, 14:00 WIB
PRNewsWire
View Source
Bullish
WhiteFiber reports Q3 revenue growth, $300M financing, and $700M new cloud contracts boosting 2027 outlook

WhiteFiber announced Q3 2026 results with 19% revenue growth to $24 million, driven by cloud and colocation services. The company secured a $300 million financing facility for its NC-1 data center and signed over $700 million in new cloud service contracts, positioning for significant revenue growth in 2027. Despite a net loss impacted by a large conversion expense, adjusted EBITDA was near breakeven. WhiteFiber also expanded its data center capacity and launched a new networking solution to support AI infrastructure demand.

WhiteFiber, Inc. reports Q3 2026 results amid Technology-sector market data. For readers following this sector, here is Pluang's market snapshot as of Nov 10, 2026 18:12 WIB: Out of 150 US tech stocks, 51 rose and 89 fell. Notable movers include KLTR at USD 1.65 with a 15.38% increase and a typical hold time of 22 days, GRAB at USD 3.23 down 6.10% with 99% sell orders, and ASX at USD 36.43 up 6.02% with 57% buy orders and a 50-day hold time.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
56 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
56 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
56 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
56 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App